9 years ago

Sphere Fluidics Secures $7M for Single Cell Analysis Platform

  • Sphere Fluidics, a Cambridge, UK-based company developing a single cell analysis system, has secured $7 million in funding

  • The round, which is still open, is being led by an Asian Corporate investor, with participation from 24Haymarket, ParkWalk Advisors, and London Business Angels

  • The funds will be used to accelerate development of the manufactured version of Cyto-Mine and enable its commercial launch later this year

  • Sphere Fluidics provides Cyto-Mine® technology, an integrated device that uses picodroplet technology and microfluidics to process around 1 million heterogeneous mammalian cells in less than half a day

  • Each cell is encapsulated in a picodroplet containing growth media, which acts as a bioreactor to compartmentalize the cell and let it grow, eventually trapping secreted molecules such as antibodies, and enables selective screening of single cells to find rare lead candidates.

      • ProblemTechnology

      "Finding rare lead candidates for drug development is time consuming and expensive. Traditional methods can take months to screen cells, and often miss valuable candidates."

      Solution

      "Cyto-Mine® is a device that uses picodroplet technology and microfluidics to process around 1 million heterogeneous mammalian cells in less than half a day. Each cell is encapsulated in a picodroplet containing growth media, which acts as a bioreactor to compartmentalize the cell and let it grow, eventually trapping secreted molecules such as antibodies, and enables selective screening of single cells to find rare lead candidates."

      Covered on